Trastuzumab / PD-L1 Cancer Research Results

Tras, Trastuzumab: Click to Expand ⟱
Features:
Trastuzumab is a targeted therapy used in the treatment of certain types of cancer, most notably HER2-positive breast cancer.

It specifically targets the human epidermal growth factor receptor 2 (HER2), a protein that is overexpressed in some types of breast cancer and other cancers.
-Is a Her2 inhibitor used in breast cancer.

Trastuzumab has revolutionized the treatment of HER2-positive breast cancer, significantly improving both response rates and overall survival.
PD-L1, Programmed Death-Ligand 1: Click to Expand ⟱
Source:
Type:
PD-L1 is a protein that plays a crucial role in the regulation of the immune system. PD-L1 helps to prevent the immune system from attacking healthy cells by binding to its receptor, PD-1, on immune cells. However, some cancer cells can exploit this mechanism by expressing high levels of PD-L1, which can help them evade immune detection.
PD-L1 has become a key target for cancer immunotherapy, particularly in the development of checkpoint inhibitors.

PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype.
PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers.
Scientific Papers found: Click to Expand⟱
6136- CHr,  Tras,    Synergistic anticancer effects of Chrysin and trastuzumab in HER2-Positive breast cancer cells
- in-vitro, BC, SkBr3 - in-vitro, BC, BT474 - in-vitro, Nor, MCF10
eff↑, HER2/EBBR2↓, p‑STAT3↓, PD-L1↓, ChemoSen↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑STAT3↓, 1,  

Immune & Inflammatory Signaling ⓘ

PD-L1↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 1,  

Clinical Biomarkers ⓘ

HER2/EBBR2↓, 1,   PD-L1↓, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PD-L1, Programmed Death-Ligand 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:260  Target#:243  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page